Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
SYN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-3.24%||8.37||0.7%||$585.09m|
|GILD||Gilead Sciences, Inc.||-1.10%||70.41||1.0%||$450.06m|
|REGN||Regeneron Pharmaceuticals, Inc.||-3.10%||619.07||2.7%||$422.20m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.11%||183.41||1.9%||$248.50m|
|ISEE||IVERIC bio, Inc.||6.90%||17.50||0.0%||$218.29m|
|LIFE||aTyr Pharma, Inc.||-3.42%||9.90||2.1%||$159.03m|
|KDMN||Kadmon Holdings, Inc.||0.11%||8.84||0.8%||$135.49m|
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.